Xonimide50 mg

Xonimide is an antiepileptic medicine used mainly to control certain types of seizures.

Established / FDA-approved use

• Adjunctive (add-on) therapy in the treatment of partial-onset seizures in adults with epilepsy, used together with other antiepileptic drugs.

Off-label uses (not FDA-approved; used in select clinical settings based on limited evidence)

• Migraine prophylaxis (off-label; based on smaller trials, generally considered a second-line option).
• Adjunct for weight management in certain obesity or binge-eating contexts (off-label; not an approved weight-loss indication).

The decision to use Xonimide for any indication should be individualized by a physician based on the patient's seizure type, response, and tolerability.

Each tablet/capsule contains Zonisamide INN as the active ingredient, along with pharmaceutically acceptable excipients. Strength and dosage form vary by product; check the product label for the exact amount of Zonisamide per unit.

Xonimide is a sulfonamide-derivative antiepileptic (anticonvulsant) medicine chemically unrelated to other major classes of antiepileptic drugs. It is used as adjunctive treatment for partial-onset seizures in adults with epilepsy. Xonimide has a long elimination half-life, which generally allows once- or twice-daily dosing after titration.

Anticonvulsant / Antiepileptic agent - sulfonamide-derivative class (chemically distinct from hydantoins, barbiturates, and other common antiepileptic classes).

The precise mechanism by which Zonisamide exerts its antiseizure effect is not fully established, but is believed to involve multiple actions:

• Blockade of voltage-gated sodium channels, stabilizing neuronal membranes and reducing repetitive neuronal firing.
• Reduction of T-type (low-threshold) calcium currents, which may reduce synchronized neuronal firing.
• Weak inhibition of carbonic anhydrase, contributing to some adverse effects (e.g., metabolic acidosis, kidney stones) but not considered the primary antiseizure mechanism.

Zonisamide is well absorbed orally, extensively bound to erythrocytes, metabolized mainly by CYP3A4, and has an elimination half-life of roughly 60 hours in the absence of enzyme-inducing co-medications.

Xonimide is taken by mouth, usually once or twice daily, with or without food; taking it consistently with food may reduce stomach upset.

• Capsules should be swallowed whole with water; do not crush or chew unless the specific formulation is designed to be chewed/dispersed (e.g., dispersible tablets, which may be dispersed in a small amount of water immediately before taking).
• Take at the same time(s) each day to maintain steady blood levels.
• Do not stop Xonimide suddenly without consulting a physician, as abrupt discontinuation can precipitate seizures or seizure clusters; when stopping, the dose should be tapered gradually under medical supervision.
• Maintain adequate fluid intake during treatment to reduce the risk of kidney stones (see Precautions and Warnings).

Clinically significant interactions with Xonimide include:

• CYP3A4-inducing antiepileptics (e.g., phenytoin, carbamazepine, phenobarbital): can substantially shorten the elimination half-life of Xonimide, reducing its levels and requiring dose adjustment.
• Strong CYP3A4 inhibitors (e.g., certain azole antifungals, some protease inhibitors): may increase Xonimide exposure; monitor for increased adverse effects.
• Other carbonic anhydrase inhibitors (e.g., topiramate, acetazolamide): concomitant use with Xonimide increases the risk and severity of metabolic acidosis and kidney stone formation.
• CNS depressants and alcohol: additive sedation, dizziness, and cognitive impairment when combined with Xonimide.

Inform the physician or pharmacist of all other medicines being taken before starting Xonimide.

Common side effects of Xonimide (generally dose-related) include:

• Somnolence (sleepiness) and fatigue
• Dizziness and ataxia (unsteadiness)
• Decreased appetite/anorexia
• Agitation, irritability, or difficulty concentrating
• Nausea and gastrointestinal upset
• Headache

Serious but less common reactions (skin reactions, metabolic acidosis, kidney stones, mood/behavioral changes, eye symptoms) are described fully under Precautions and Warnings; contact a physician promptly if these occur.

Xonimide has shown teratogenic and embryo-fetal toxicity in animal studies. In humans, antiepileptic drugs as a class, including Xonimide, are associated with increased risk of congenital malformations. Xonimide should be used during pregnancy only if clearly needed and if the potential benefit of seizure control justifies the potential risk to the fetus; abrupt discontinuation is not advised due to the risk of seizure recurrence. A physician should be consulted regarding pregnancy planning, folic acid supplementation, and monitoring.

Xonimide passes into breast milk. Breastfeeding while using Xonimide should only be undertaken after consulting a physician, weighing the benefits of breastfeeding against potential effects (e.g., sedation) on the infant.

Important precautions and warnings for Xonimide include:

• Serious skin reactions: Because Xonimide is a sulfonamide derivative, it carries a risk of serious, occasionally fatal, hypersensitivity reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and other sulfonamide-related reactions (e.g., agranulocytosis, aplastic anemia). Discontinue immediately and seek medical care if a rash or signs of hypersensitivity develop.
• Oligohidrosis and hyperthermia: Xonimide can decrease sweating and increase body temperature, especially in children and during hot weather or vigorous exercise; monitor for reduced sweating and overheating, and ensure adequate hydration and cooling.
• Metabolic acidosis: Xonimide can cause hyperchloremic, non-anion gap metabolic acidosis, more common and more severe in children. Serum bicarbonate should be measured at baseline and periodically during treatment, particularly in patients with renal disease, respiratory disorders, severe illness, or those on a ketogenic diet.
• Kidney stones: Increased risk of nephrolithiasis; maintain adequate fluid intake and hydration throughout treatment with Xonimide.
• Suicidal thoughts/behavior: Like other antiepileptic drugs, Xonimide is associated with a small increased risk of suicidal ideation or behavior; monitor for mood changes, depression, or unusual behavior.
• Cognitive/psychiatric effects: Difficulty concentrating, memory problems, depression, psychosis, or irritability can occur with Xonimide; use caution when driving or operating machinery.
• Acute myopia with secondary angle-closure glaucoma: A rare but serious eye condition presenting as acute vision changes and eye pain, typically within the first month of starting Xonimide. Discontinue promptly and seek urgent ophthalmologic care if symptoms occur.
• Pregnancy: Use with caution, weighing seizure-control benefit against teratogenic risk (see Pregnancy and Lactation).
• Do not stop abruptly: Discontinuing Xonimide suddenly can precipitate seizures; taper under medical supervision.

Overdose of Xonimide may cause severe drowsiness, nausea, dizziness, ataxia, bradycardia, respiratory depression, and reduced consciousness. There is no specific antidote.

If an overdose of Xonimide is suspected, seek immediate medical attention or contact a poison control center/emergency services right away. Do not attempt home treatment; supportive care and monitoring in a medical facility are required.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric use

Safety and efficacy of Xonimide for partial-onset seizures have not been established in children below the approved age threshold in many regulatory labels; where used in younger children, oligohidrosis, hyperthermia, and metabolic acidosis risks are higher and require close monitoring (see Precautions and Warnings).

Elderly

Use Xonimide with caution in elderly patients, who may have reduced renal function; dose titration should be slower with closer monitoring.

Renal/hepatic impairment

Slower titration and closer monitoring are advised; avoid use in severe renal impairment unless closely supervised (see Dosage and Administration).

Pregnancy and lactation

See Pregnancy and Lactation section for detailed guidance on use of Xonimide during pregnancy and breastfeeding.

Duration of treatment with Xonimide is individualized based on seizure control, tolerability, and the underlying epilepsy syndrome; it is typically used long-term as part of ongoing epilepsy management and periodically reassessed by the treating physician. Any decision to reduce or stop Xonimide should involve a gradual taper under medical supervision rather than abrupt discontinuation.

Anticonvulsants; Antiepileptic drugs; Sulfonamide-derivative anticonvulsants.

Zonisamide stabilizes neuronal membranes and suppresses neuronal hypersynchronization primarily through blockade of voltage-gated sodium channels and reduction of T-type calcium currents, with weak carbonic anhydrase inhibitory activity as a secondary effect.

C

The safety and efficacy of Xonimide have not been fully established in young children in many regulatory labels; use in pediatric patients should follow local approved labeling and specialist supervision. Children appear to be at higher risk than adults for oligohidrosis, hyperthermia, and metabolic acidosis while taking Xonimide, so close monitoring of sweating, body temperature, and serum bicarbonate is recommended, especially in hot weather (see Precautions and Warnings).